IL6 and Miyoshi myopathy: For example, siltuximab, an anti-IL-6 monoclonal antibody alone did not improve progression free survival (PFS) or overall survival (OS) in two separate Phase 2 clinical trials for patients with relapsed or refractory MM (Voorhees et al., 2013; NCT00401843).